A “Disclosure Defense” in Liability Law

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-03-02-2005, Volume 29, Issue 3

In this time of liability reform, pharma deserves the chance to align its economic interests with its ethical obligations to the patient.

Related Content:

From the EditorProcess ValidationQuality SystemsViewpointsPharmaceutical Technology-03-02-2005
PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy
EMA’s CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer’s Disease
J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer